Home/Pipeline/αvβ3-targeted ADC

αvβ3-targeted ADC

Glioblastoma

PreclinicalLead Optimization

Key Facts

Indication

Glioblastoma

Phase

Preclinical

Status

Lead Optimization

Company

Xintela

About Xintela

Xintela AB is a biomedical company leveraging its unique integrin platform to address high unmet needs in cartilage damage and aggressive cancers. Founded in 2013 and based in Lund, Sweden, its strategy centers on developing a dual pipeline: XSTEM, an α10β1-selected mesenchymal stem cell therapy for osteoarthritis, and targeted oncology programs against the αvβ3 integrin. As a publicly traded entity on Nasdaq First North, Xintela is progressing its lead candidate through clinical validation while exploring strategic partnerships to accelerate development.

View full company profile

Therapeutic Areas

Orthopedics (Regenerative Medicine)Oncology

Other Glioblastoma Drugs

Drug	Company	Phase	Status
Ropidoxuridine (IPdR)	Shuttle Pharmaceuticals	Phase 2	Active
LNTH-2505	Lantheus Medical Imaging	Preclinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
Glioblastoma Moonshot	Owkin	Research	Open Project
OPC-001 (PDC Candidate)	Oncopeptides	Phase 1/Window-of-Opportunity	Active (Fast-Track Designation)
GLIX1	Hemispherian	Phase 1	Active
InC01	InCephalo Therapeutics	Pre-clinical	Active
Glioblastoma Combination Therapy	JLP Health	Pre-clinical	Active
ENV105	Kairos Pharma	IND Cleared	Active
LMP744	Gibson Oncology	Phase 2	Active
BEA-17	Beactica Therapeutics	Pre-clinical	Active
SFK Inhibitor	Lead Discovery Siena	Preclinical	Active